Clinical Trials for Cervical Cancer

Phase Ib Study of Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy (SBRT) in Patients With Locoregionally Recurrent, Refractory, or Oligometastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with locoregionally recurrent, refractory, or oligometastatic (≤4 lesions) HNSCC (non-nasopharyngeal; CPS >1%) receive losartan lead-in, SBRT to involved sites, then pembrolizumab; prior RT/systemic therapy allowed but no prior PD‑1/PD‑L1 and no current ACEi/ARB. Losartan (angiotensin II type 1 receptor blocker) is used to remodel tumor stroma and enhance radiation/immunotherapy efficacy, followed by PD‑1 blockade with pembrolizumab.

ClinicalTrials.gov ID: NCT06211335

Study of Intratumoral Injections of VLPONC-01 in Head and Neck Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with head and neck squamous cell carcinoma eligible for intratumoral injection: either unresectable/recurrent/metastatic disease post–PD-1/PD-L1 and standard therapies (IT VLPONC-01 alone) or resectable stage I–IVb disease planned for surgery (neoadjuvant pembrolizumab with or without IT VLPONC-01). VLPONC-01 is a virus replicon particle–delivered self-amplifying RNA encoding IL-12 to drive local innate/adaptive immune activation and potentially sensitize tumors to PD-1 blockade.

ClinicalTrials.gov ID: NCT06736379

Pilot Phase II Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy With PD-1 Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with recurrent/metastatic HNSCC who have progressed on or were intolerant to prior PD‑1–based therapy receive single‑agent cetuximab (weekly IV), an anti‑EGFR monoclonal antibody that blocks ligand-induced signaling and mediates ADCC. Single-arm study assessing response rate, with secondary PFS/OS and safety.

ClinicalTrials.gov ID: NCT04375384

Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with untreated metastatic NSCLC (squamous or nonsquamous without targetable drivers) or incurable recurrent/metastatic HNSCC eligible for pembrolizumab-based first line receive an alternating induction schedule of chemoimmunotherapy cycles interspersed with pembrolizumab monotherapy. Regimens use standard backbones (carboplatin/paclitaxel or nab-paclitaxel for squamous NSCLC; carboplatin/pemetrexed with optional pemetrexed maintenance for nonsquamous NSCLC; carboplatin/5-FU for HNSCC) plus pembrolizumab, an anti–PD-1 antibody.

ClinicalTrials.gov ID: NCT05358548

A Prospective Cohort Study of Integrating Radiotherapy Into Chemotherapy With Pembrolizumab and Bevacizumab in Newly Diagnosed Stage IVB Cervical Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with newly diagnosed, untreated stage IVB, PD-L1–positive cervical cancer (squamous/adenocarcinoma/adenosquamous), ECOG 0–1, receive induction cisplatin/paclitaxel plus pembrolizumab (anti–PD-1) and bevacizumab (anti-VEGF), followed by definitive pelvic EBRT with brachytherapy while continuing pembrolizumab/bevacizumab. Designed to assess safety and efficacy of adding definitive radiotherapy to the current chemoimmunotherapy/bevacizumab backbone; excludes prior systemic therapy/RT or checkpoint inhibitors and active autoimmune disease.

ClinicalTrials.gov ID: NCT06543576

KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with locoregionally recurrent or second primary HNSCC after prior radiotherapy (≥30 Gy), confined to a single target (total GTV <7.5 cm) without metastases, are randomized to SBRT re-irradiation with or without pembrolizumab. Pembrolizumab is an anti–PD-1 monoclonal antibody added every 3 weeks for up to 2 years, with crossover permitted at progression.

ClinicalTrials.gov ID: NCT03546582

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable locally advanced (neck-confined after prior surgery/radiation) or metastatic anaplastic/undifferentiated thyroid cancer, ECOG 0–1, and no prior PD‑1/PD‑L1 therapy receive pembrolizumab 200 mg IV q3w for up to 2 years. Pembrolizumab is a PD‑1 immune checkpoint inhibitor restoring antitumor T-cell activity; key exclusions include active CNS disease (unless treated/stable), autoimmune disease requiring systemic therapy, chronic immunosuppression, and active HIV/HBV/HCV.

ClinicalTrials.gov ID: NCT05119296

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with iodine‑avid but RAI‑insufficient papillary/follicular DTC with unresectable locoregional invasion and/or distant metastases receive individualized combination therapy of systemic I‑131 and external beam radiotherapy, using integrated dosimetry to escalate cumulative dose (target ≥80 Gy) to selected lesions. Aims to assess safety and preliminary efficacy with coordinated RAI+XRT planning in patients with adequate organ function and no contraindications to TSH stimulation or radiation.

ClinicalTrials.gov ID: NCT04892303

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Adults with unresectable locally advanced or metastatic NSCLC (EGFR/ALK–, PD-L1 TPS ≥50%), HNSCC (PD-L1 CPS ≥20), or melanoma (any PD-L1/BRAF) who are either ICI-naive or have progressed on prior PD‑1/PD‑L1 therapy receive pembrolizumab plus CJRB‑101, an oral live biotherapeutic (Leuconostoc mesenteroides) designed to modulate the tumor-immune microenvironment (macrophage repolarization, APC activation, ↑CD8+ infiltration) to enhance PD‑1 blockade. Key exclusions include EGFR/ALK+ NSCLC, nasopharyngeal carcinoma, uncontrolled brain mets, significant autoimmune disease/IBD, key infections, and inability to take oral capsules.

ClinicalTrials.gov ID: NCT05877430

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable, recurrent, or metastatic androgen receptor–positive salivary gland carcinoma (ECOG 0–1), including previously treated patients without prior ADT or checkpoint inhibitors, receive goserelin (GnRH agonist ADT) plus pembrolizumab (anti–PD-1) until progression or toxicity. Stable, treated brain metastases are allowed; key exclusions include active autoimmune disease requiring systemic therapy and significant immunosuppression.

ClinicalTrials.gov ID: NCT03942653